CAS: 52328-05-9; O-Methylisourea Hemisulfate

相似化合物

5329-33-9 29427-58-5 1185239-70-6

上下游产品

CAS号186435-66-5 6-氨基-2-甲氧基嘧啶-4-醇 | CAS号90057-07-1 6-羟基-2-甲氧基-7-脱氮嘌呤 | CAS号1450-93-7 2-氨基咪唑硫酸盐 | CAS号14191-90-3 L-去甲精氨酸盐酸盐 | CAS号168627-33-6 N-cyclopropylgu... | CAS号61640-58-2 methyl N'-(3,5-... | CAS号6331-57-3 2-cyclohexylgua...

甲醇,氰胺置于硫酸体系中,化学反应 3.0H,以100%的收率获得产物o-甲基异脲 半硫酸盐
参考文献:Process For The Preparation Of 9-Deazaguanine Derivatives
标题:Process For The Preparation Of 9-Deazaguanine Derivatives
摘要:9-脱氧鸟嘌呤的衍生物是通过将醛或酮与二烷基氨基丙二酸酯反应制备相应的烯胺.然后,将烯胺与碱反应形成环状吡咯.将环状吡咯与尿素化合物或羰基脲酸衍生物反应,以提供受保护的胍基化合物.通过与三氟乙酸或烷氧化物或氢氧化物反应,然后用酸中和将胍基化合物转化为所需的9-脱氧鸟嘌呤衍生物.

专利信息

专利号:US-2024317750-A1
优先权日:2021-06-24
标 题 :An Efficient Process for the Synthesis of Methylliberine and Polymorphs Thereof
发明人：KANUMURU RAHUL RAJU; SHAJI GEORGE KOCHUMALAYIL; VANA MURALI MOHANARAO; SURANENI RAVIKUMAR; ANINDYA SIL
权利人:FERTIS INDIA PVT LTD
摘要:The present invention discloses a synthetic procedure for the preparation of Methylliberine and its polymorphs thereof in a simple and efficient manner.

专利号:EP-1401829-B1
优先权日:2001-06-15
标题 :Novel heterocyclic antibacterial compounds
发明人：ZHI CHENGXIN; WRIGHT GEORGE E
权利人:MICROBIOTIX INC
摘要:The invention provides heterocyclic organic compounds that inhibit bacterial DNA polymerase IIIC and type II bacterial topoisomerase. The invention further provides compounds that are useful as intermediates in the synthesis of such heterocyclic organic compounds. Syntheses and uses of such heterocyclic organic molecules are also described.

专利号:US-6777420-B2
优先权日:2001-06-15
标题 :Heterocyclic antibacterial compounds
发明人：ZHI CHENGXIN; WRIGHT GEORGE E
权利人:MICROBIOTIX INC
摘要:The invention provides heterocyclic organic compounds that inhibit bacterial DNA polymerase IIIC and type II bacterial topoisomerase. The invention further provides compounds that are useful as intermediates in the synthesis of such heterocyclic organic compounds. Syntheses and uses of such heterocyclic organic molecules are also described.

专利号:US-6172066-B1
优先权日:1996-05-16
标 题:Dihydropyrimidines and uses thereof
发明人：NAGARATHNAM DHANAPALAN; WONG WAI C; MIAO SHOU WU; PATANE MICHAEL A; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

专利号:US-6228861-B1
优先权日:1995-11-16
标题 :Dihydropyrimidines and uses thereof
发明人：NAGARATHNAM DHANAPALAN; WONG WAI C; MIAO SHOU WU; GLUCHOWSKI CHARLES; PATANE MICHAEL A
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

专利号:US-6245773-B1
优先权日:1996-05-16
标题:5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
发明人：WONG WAI C; LAGU BHARAT; NAGARATHNAM DHANAPALAN; MARZABADI MOHAMMAD R; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds of the following formula: n which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.